Vitiligo pp 13-24 | Cite as

Epidemiology, Definitions and Classification

  • Alain TaïebEmail author
  • Mauro Picardo

Core Messages

  • › Vitiligo occurs worldwide with an estimated overall prevalence of less than 0.5% in population-based studies.

  • › Vitiligo vulgaris/NSV (non-segmental vitiligo) is an acquired chronic pigmentation disorder characterized by white patches, often symmetrical, which usually increase in size with time, corresponding to a substantial loss of functioning epidermal, and sometimes hair follicle melanocytes.

  • › Segmental vitiligo (SV) is defined descriptively as for NSV, except for a unilateral distribution (“asymmetric vitiligo”) that may totally or partially match a cutaneous segment such as a dermatome, but not necessarily.

  • › NSV and SV may coexist, and in this case SV lesions are usually more refractory to treatment.


Atopic Dermatitis Toxic Epidermal Necrolysis Mycosis Fungoides Pityriasis Versicolor Oculocutaneous Albinism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Alkhateeb A, Fain PR, Thody A et al (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16:208–214PubMedCrossRefGoogle Scholar
  2. 2.
    Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920PubMedCrossRefGoogle Scholar
  3. 3.
    Berger TG, Kiesewetter F, Maczek C et al (2006) Psoriasis confined strictly to vitiligo areas—a Koebner-like phenomenon? J Eur Acad Dermatol Venereol 20:178–183PubMedCrossRefGoogle Scholar
  4. 4.
    Boisseau-Garsaud AM, Garsaud P, Calès-Quist D et al (2000) Epidemiology of vitiligo in the French West Indies (Isle of Martinique). Int J Dermatol 39:18–20PubMedCrossRefGoogle Scholar
  5. 5.
    Boissy RE, Manga P (2004) On the etiology of contact/ occupational vitiligo. Pigment Cell Res 17:208–214PubMedCrossRefGoogle Scholar
  6. 6.
    Brandrup F, Holm N, Grunnet N et al (1982) Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 62:229–236PubMedGoogle Scholar
  7. 7.
    Cario-André M, Ardilouze L, Pain C et al (2006) Imatinib mesilate inhibits melanogenesis in vitro. Br J Dermatol 155:493–494PubMedCrossRefGoogle Scholar
  8. 8.
    Das SK, Majumder PP, Chakraborty R et al (1985) Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol 2:71–78PubMedCrossRefGoogle Scholar
  9. 9.
    Duffy DL, Spelman LS, Martin NG (1993) Psoriasis in Australian twins. J Am Acad Dermatol 29:428–434PubMedCrossRefGoogle Scholar
  10. 10.
    De Vijlder HC, Westerhof W, Schreuder GM et al (2004) Difference in pathogenesis between vitiligo vulgaris and halo nevi associated with vitiligo is supported by an HLA association study. Pigment Cell Res 17:270–274PubMedCrossRefGoogle Scholar
  11. 11.
    Gauthier Y, Cario-Andre M, Taieb A (2003) A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 16:322–332PubMedCrossRefGoogle Scholar
  12. 12.
    Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic sig-nificance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709–718PubMedCrossRefGoogle Scholar
  13. 13.
    Guillet G, Helenon R, Gauthier Y et al (1988) Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol 15:286–289PubMedCrossRefGoogle Scholar
  14. 14.
    Hann SK, Lee HJ (1996) Segmental vitiligo: clinical find-ings in 208 patients. J Am Acad Dermatol 35:671–674PubMedCrossRefGoogle Scholar
  15. 15.
    Hartmann A, Bedenk C, Keikavoussi P et al (2008) Vitiligo and melanoma-associated hypopigmentation (MAH):shared and discriminative features. J Dtsch Dermatol Ges 6:1053–1059PubMedCrossRefGoogle Scholar
  16. 16.
    Howitz J, Brodthagen H, Schwartz M et al (1977) Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 113:47–52PubMedCrossRefGoogle Scholar
  17. 17.
    Kim YC, Kim YJ, Kang HY et al (2008) Histopathologic features in vitiligo. Am J Dermatopathol 30:112–116PubMedCrossRefGoogle Scholar
  18. 18.
    Koga M (1977) Vitiligo: a new classification and therapy. Br J Dermatol 97:255–261PubMedCrossRefGoogle Scholar
  19. 19.
    Kumarasinghe SP, Tan SH, Thng S et al (2006) Progressive macular hypomelanosis in Singapore: a clinico-pathological study. Int J Dermatol 45:737–742PubMedCrossRefGoogle Scholar
  20. 20.
    Lee HS, Chun YS, Hann SK (1999) Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients. J Am Acad Dermatol 40:21–26PubMedCrossRefGoogle Scholar
  21. 21.
    Liu JB, Li M, Yang S et al (2005) Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp Dermatol 30:327–331PubMedCrossRefGoogle Scholar
  22. 22.
    Mashiah J, Brenner S (2008) Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imi-quimod. Clin Exp Dermatol 33:74–76PubMedGoogle Scholar
  23. 23.
    Mulekar SV, Al Issa A, Asaad M et al (2006) Mixed vitiligo. J Cutan Med Surg 10:104–107PubMedGoogle Scholar
  24. 24.
    Oplatek A, Brown K, Sen S, et al (2006) Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 27:26–33PubMedCrossRefGoogle Scholar
  25. 25.
    Relyveld GN, Dingemans KP, Menke HE et al (2008) Ultrastructural findings in progressive macular hypomelano-sis indicate decreased melanin production. J Eur Acad Dermatol Venereol 22:568–574PubMedCrossRefGoogle Scholar
  26. 26.
    Schallreuter KU, Krüger C, Rokos H et al (2007) Basic research confirms coexistence of acquired Blaschkolinear Vitiligo and acrofacial Vitiligo. Arch Dermatol Res 299:225–230PubMedCrossRefGoogle Scholar
  27. 27.
    Schallreuter KU, Krüger C, Würfel BA et al (2008) From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. Int J Dermatol 47:743–753PubMedCrossRefGoogle Scholar
  28. 28.
    Schultz Larsen F (1993) Atopic dermatitis: a genetic-epide-miologic study in a population-based twin sample. J Am Acad Dermatol 28:719–723PubMedCrossRefGoogle Scholar
  29. 29.
    Sehgal VN, Srivastava G (2007) Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 73:149–156PubMedCrossRefGoogle Scholar
  30. 30.
    Singh M, Singh G, Kanwar AJ, Belhaj MS (1985) Clinical pattern of vitiligo in Libya. Int J Dermatol 24:233–235PubMedCrossRefGoogle Scholar
  31. 31.
    Singh ZN, Tretiakova MS, Shea CR, Petronic-Rosic VM (2006) Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Mod Pathol 19:1255–1260PubMedCrossRefGoogle Scholar
  32. 32.
    Smith DA, Burgdorf WH (1984) Universal cutaneous depig-mentation following phenytoin-induced toxic epidermal necrolysis. J Am Acad Dermatol 10:106–109PubMedCrossRefGoogle Scholar
  33. 33.
    Spritz RA (2007) The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res 20:271–278PubMedCrossRefGoogle Scholar
  34. 34.
    Taïeb A, Picardo M; VETF Members (2007) The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 20:27–35PubMedCrossRefGoogle Scholar
  35. 35.
    Thoma W, Krämer HJ, Mayser P (2005) Pityriasis versicolor alba. J Eur Acad Dermatol Venereol 19:147–152PubMedCrossRefGoogle Scholar
  36. 36.
    Westerhof W, Relyveld GN, Kingswijk MM et al (2004) Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis. Arch Dermatol 140:210–214PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Istituto Dermatologico San GallicanoRomaItaly
  2. 2.Service de Dermatologie De Dermatologie PédiatriqueCentre de référence des maladies rares de la Peau Hôpital Saint-AndréBordeauxFrance

Personalised recommendations